Egyptian contractor Korra Energi has been appointed for the construction of two factory buildings and an office building for veterinary vaccines manufacturer Mevac, reported Zawya.

These facilities form Mevac’s veterinary vaccine project in the Ismailia Governorate of Egypt.

US-based Kemin Industries owns a majority share in Mevac, which is considered a leading private manufacturer of veterinary vaccines in both Egypt and across the Middle East and Africa region.

Korra Energi chair Ayman Korra has revealed that Mevac is investing E£2.2bn in this three-building project.

Construction of this project is expected to be finished within 15 months.

Korra added: “We are proud that we are the first choice for customers, especially in the health, pharmaceutical and hotel sectors. We are also proud of our contribution to the implementation of national projects.”

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

One building, spanning 6,250m² in area, will be used for the manufacture of avian flu vaccines. This facility is set to have an annual production capacity of 3.6 billion doses.

A second building will be spread over 8,367m² and will house a factory to produce genetically modified vaccines for the livestock and poultry industries. This factory is set to have a capacity of four billion doses of loaded vaccines and five billion doses of live vaccines annually.

A research and development centre, as well as offices, will be housed in the third and final building, which will have a floor space of 9,000m².